RecruitingPhase 3NCT04204252

Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"

Studying Alpha-1-antitrypsin deficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Kamada, Ltd.
Principal Investigator
Jan Stolk, Prof
LUMC
Intervention
Alpha 1-Antitrypsin(drug)
Enrollment
220 enrolled
Eligibility
18-65 years · All sexes
Timeline
20192031

Study locations (9)

Collaborators

Syneos Health

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04204252 on ClinicalTrials.gov

Other trials for Alpha-1-antitrypsin deficiency

Additional recruiting or active studies for the same condition.

See all trials for Alpha-1-antitrypsin deficiency

← Back to all trials